BRINEURA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BRINEURA (BRINEURA).
BRINEURA (cerliponase alfa) is a recombinant human tripeptidyl peptidase-1 (TPP1) enzyme that replaces deficient TPP1 in patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease). It hydrolyzes tripeptides from the N-terminus of proteins, reducing accumulation of autofluorescent lipopigments in lysosomes.
| Metabolism | Cerliponase alfa is a recombinant protein expected to be catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes identified. |
| Excretion | Primarily catabolized via peptide hydrolysis to small peptides and amino acids; renal excretion of intact enzyme is negligible (<1% of dose). |
| Half-life | Terminal half-life is approximately 3 to 4 days (mean 3.5 days) in pediatric patients, supporting weekly intravenous dosing. |
| Protein binding | Negligible protein binding (<1%) as it is a recombinant enzyme. |
| Volume of Distribution | Approximately 1.54 L/kg (pediatric patients), indicating distribution primarily within extracellular fluid and tissues. |
| Bioavailability | Intravenous: 100% (only route of administration); not bioavailable via oral or other routes due to protein degradation. |
| Onset of Action | Intravenous: Reduction in substrate (globotriaosylceramide; Gb3) levels observed within 2 weeks of starting therapy; clinical improvement in pain crises may occur over several weeks to months. |
| Duration of Action | Duration of action is approximately 1 week based on sustained reduction in plasma Gb3 levels with weekly IV infusions; maximal effect may require up to 6 months of treatment. |
400 mg every 2 weeks via intravenous infusion over 1.5 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required in renal impairment, including end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Weight-based dosing: 30 mg/kg every 2 weeks via intravenous infusion, maximum 400 mg per dose. |
| Geriatric use | No specific dose adjustment for elderly patients; use caution due to possible concomitant diseases and medications. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BRINEURA (BRINEURA).
| Breastfeeding | No human data on excretion in breast milk. M/P ratio unknown. Given high molecular weight (approximately 150 kDa), excretion into milk is unlikely but not excluded. Caution advised; consider developmental benefits of breastfeeding vs potential adverse effects. |
| Teratogenic Risk | Insufficient human data. In animal studies, no evidence of teratogenicity at clinically relevant doses. First trimester: unknown risk; second and third trimesters: theoretical risk due to potential interference with sphingolipid metabolism. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Risk of life-threatening or serious hypersensitivity reactions, including anaphylaxis, and risk of device-related complications (e.g., infection, device malfunction) requiring hospitalization or surgical intervention.
| Serious Effects |
["Intraventricular access device that is not functioning or is infected","Known hypersensitivity to cerliponase alfa or any component of the formulation (including bovine-derived products)"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis: premedicate and monitor during infusion","Device-related complications: infection, device malfunction, or intraventricular access device removal","Cardiovascular effects: bradycardia, hypertension, hypotension during or after infusion","Laboratory abnormalities: low CSF protein, low CSF glucose","Risk of meningitis, ventriculitis, and other CNS infections"] |
| Food/Dietary | No clinically significant food interactions have been identified. Administer without regard to meals. |
Loading safety data…
| Fetal Monitoring |
| Monitor liver function tests (ALT, AST, bilirubin) monthly during pregnancy and postpartum. Assess fetal growth via ultrasound every 4-6 weeks due to potential for intrauterine growth restriction. Monitor for signs of infusion reactions during administration. |
| Fertility Effects | No human data on fertility effects. In animal studies, no adverse effects on male or female fertility at clinically relevant doses. Theoretical concern due to enzyme replacement therapy affecting sphingolipid metabolism; clinical significance unknown. |
| Clinical Pearls | BRINEURA (cerliponase alfa) is a recombinant human tripeptidyl peptidase-1 (TPP1) enzyme replacement therapy for neuronal ceroid lipofuscinosis type 2 (CLN2 disease). Administer via intraventricular infusion using a surgically implanted reservoir and ventricular catheter. Pre-treat with antihistamines and antipyretics to mitigate infusion-associated reactions. Monitor for device-related complications, including infection, leakage, and obstruction. Discontinue if hypersensitivity or anaphylaxis occurs. |
| Patient Advice | BRINEURA is given as an infusion directly into the fluid around the brain every 2 weeks. It requires a surgical procedure to place a port and catheter. · Common side effects include headache, seizure, vomiting, fever, and irritability. Serious allergic reactions or infections of the device or nervous system can occur. · Contact your healthcare provider immediately if you experience severe headache, stiff neck, sensitivity to light, confusion, or signs of an allergic reaction (hives, difficulty breathing, swelling of the face or throat). · Do not skip or delay infusions. Regular treatment is essential to slow the progression of CLN2 disease. · Keep all appointments for infusion and monitoring of your device. |